Carbidopa and Levodopa orally disintegrating tablets (ODT), indicated for the treatment of idiopathic Parkinson’s disease, are the generic version of Schwarz Pharma’s Parcopa ODT. This product, which Mylan
The trial will be conducted in two parts. In Phase I, the objective will be to determine the dose of Cloretazine in combination with daunorubicin and cytarabine. Phase
Jake Philip, CEO of Biolase, said: “While we have had a number of recent successes in laser and consumable patents and global product launches, this is our first
The initiation of this single-arm open label observational safety study follows a successful pivotal Phase III study of Dyloject in patients with postoperative abdominal pain. Additionally, the company
The opening of additional sites in Germany is intended to compensate for a lower than expected patient enrollment rate thus far in Sweden. These sites have been added
Used in conjunction with the company’s proprietary CellOptics platform, a robotic microscopy system, oncoFISH cervical provides the physician, while still adhering to current practice guidelines, with an assessment
The approved EraGen molecular diagnostic tests are performed on the company’s MultiCode-RTx real-time polymerase chain reaction (PCR) system. The MultiCode-RTx system reportedly simplifies and enhances traditional real-time PCR
The acquisition of Orthos represents Atrium’s second Netherlands-based acquisition for 2008. Atrium has previously announced the acquisition of MCO Health, a manufacturer and distributor of nutritional supplements. AOV
Teva is manufacturing and distributing the product, under license, as part of a license and distribution agreement entered into between Teva and Exela PharmSci, a Reston, Virginia pharmaceutical
The trial was designed to evaluate the effect of SCV-07 on hepatitis C viral load, as well as on other measures of immune response. SCV-07 demonstrated activity in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.